BRII-179 shows its strongest signal before treatment, not during it, as Brii Bio reshapes its hepatitis B cure strategy
ENRICH recorded HBsAg loss rates of 42.9% and 40% after BRII-179 priming, while a concurrent triple regimen underperformed expectations and a recalled assay kit now requires retesting of another cohort.